Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction

The biochemistry of apoptosis

2000 • 7,314 citations

Apoptosis by Death Factor

1997 • 5,038 citations

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 • 2,916 citations

Inhibition of death receptor signals by cellular FLIP

1997 • 2,577 citations

Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

1996 • 1,281 citations

Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

1999 • 1,260 citations

Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance

1999 • 1,168 citations

A p16 ^INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma

1995 • 1,147 citations

Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma

1996 • 1,110 citations

Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2

1994 • 991 citations

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

1994 • 850 citations

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand

2000 • 805 citations

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1

1999 • 803 citations

Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity

1998 • 789 citations

Fas-Induced Caspase Denitrosylation

1999 • 742 citations

Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles

2002 • 739 citations

A listing of human tumor antigens recognized by T cells

2001 • 708 citations

Altered Peptide Ligand–Induced Partial T Cell Activation: Molecular Mechanisms and Role in T Cell Biology

1996 • 698 citations

Downregulation of Fas ligand by shedding

1998 • 681 citations

Intracellular Regulation of TRAIL-Induced Apoptosis in Human Melanoma Cells

1998 • 671 citations

Fas and FasL in the homeostatic regulation of immune responses

1995 • 579 citations

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.

1996 • 542 citations

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

2001 • 535 citations

Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes

1998 • 534 citations

Nitric oxide and the regulation of gene expression

2001 • 529 citations

Nitric Oxide Protects Cultured Rat Hepatocytes from Tumor Necrosis Factor-α-induced Apoptosis by Inducing Heat Shock Protein 70 Expression

1997 • 527 citations

Loss of Functional Beta2-Microglobulin in Metastatic Melanomas From Five Patients Receiving Immunotherapy

1996 • 515 citations

High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals

1999 • 497 citations

Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinial relevance

1995 • 478 citations

Lysosome‐related organelles

2000 • 467 citations

Antigen-processing machinery breakdown and tumor growth

2000 • 444 citations

The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity

2000 • 440 citations

Nitric Oxide Inhibits Caspase-3 by S-Nitrosationin Vivo

1999 • 427 citations

Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands

1993 • 414 citations

Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?

2002 • 400 citations

Mannose 6-Phosphate/Insulin-like Growth Factor II Receptor Is a Death Receptor for Granzyme B during Cytotoxic T Cell–Induced Apoptosis

2000 • 393 citations

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

2002 • 387 citations

Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells

1999 • 385 citations

Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors

2001 • 347 citations

Essential flexibility in the T-cell recognition of antigen

1996 • 330 citations

Nitric Oxide Inhibits Fas-induced Apoptosis

1997 • 317 citations

Antitumor effect of locally produced CD95 ligand

1997 • 315 citations

Enhanced Antigen-Specific Antitumor Immunity with Altered Peptide Ligands that Stabilize the MHC-Peptide-TCR Complex

2000 • 312 citations

Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1997 • 311 citations

Activated Human T Cells Release Bioactive Fas Ligand and APO2 Ligand in Microvesicles

1999 • 302 citations

MHC antigens and tumor escape from immune surveillance

2001 • 300 citations

Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.

1995 • 296 citations

NKT cells — conductors of tumor immunity?

2002 • 289 citations

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

1997 • 286 citations

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

1996 • 285 citations

The role of FasL-induced apoptosis in immune privilege

1997 • 262 citations

Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape

2000 • 256 citations

Down-Regulation of HLA Class I Antigen-Processing Molecules in Malignant Melanoma

1999 • 249 citations

FLIP Prevents Apoptosis Induced by Death Receptors But Not by Perforin/Granzyme B, Chemotherapeutic Drugs, and Gamma Irradiation

1998 • 247 citations

Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses

1998 • 245 citations

Die and Let Live: Eliminating Dangerous Lymphocytes

1996 • 242 citations

The Fas counterattack: cancer as a site of immune privilege

1999 • 240 citations

Fas expression and function in normal and malignant breast cell lines.

1996 • 236 citations

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2?-deoxycytidine treatment

2001 • 234 citations

Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.

1999 • 218 citations

TAP off - tumors on

1997 • 215 citations

Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.

1997 • 210 citations

An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions

1999 • 197 citations

Fas and the art of lymphocyte maintenance.

1996 • 196 citations

A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer

1996 • 196 citations

beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.

1998 • 193 citations

Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway.

2001 • 189 citations

Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.

1997 • 187 citations

Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).

1996 • 182 citations

Nitric Oxide-Mediated Regulation of Chemosensitivity in Cancer Cells

2001 • 168 citations

Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

1995 • 166 citations

Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo

1998 • 166 citations

Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis

1998 • 164 citations

Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.

1994 • 163 citations

Immune privilege or inflammation? Insights into the Fas ligand enigma

2001 • 159 citations

Granzyme B Induces BID-mediated Cytochrome c Release and Mitochondrial Permeability Transition

2001 • 155 citations

Thymic Selection Generates a Large T Cell Pool Recognizing a Self-Peptide in Humans

2002 • 153 citations

Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors.

1994 • 143 citations

High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas

1998 • 143 citations

Mutations of the β₂‐microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides

1998 • 142 citations

Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9.

2002 • 137 citations

The chemoresistance of human malignant melanoma

1999 • 136 citations

Selection for β2-microglobulin mutation in mismatch repair-defective colorectal carcinomas

1996 • 130 citations

Differential Anti-MART-1/MelanA CTL Activity in Peripheral Blood of HLA-A2 Melanoma Patients in Comparison to Healthy Donors

1996 • 127 citations

CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells.

1995 • 124 citations

Interleukin 10–Mediated Immunosuppression by a Variant CD4 T Cell Epitope of Plasmodium falciparum

1999 • 122 citations

Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors

1999 • 116 citations

In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells

2002 • 105 citations

Selective Histocompatibility Leukocyte Antigen (Hla)-A2 Loss Caused by Aberrant Pre-mRNA Splicing in 624mel28 Melanoma Cells

1999 • 104 citations

Mechanisms of loss of HLA class I expression on colorectal tumor cells

1996 • 102 citations

Antiapoptotic role of endogenous nitric oxide in human melanoma cells.

2001 • 99 citations

FasL:Fas ratio--a prognostic factor in breast carcinomas.

2000 • 99 citations

High Frequency of Autologous Anti-Melanoma CTL Directed Against an Antigen Generated by a Point Mutation in a New Helicase Gene

2000 • 97 citations

A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy.

1999 • 97 citations

Qualitative and quantitative contributions of the T cell receptor zeta chain to mature T cell apoptosis.

1996 • 94 citations

Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use

1994 • 92 citations

Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.

1996 • 90 citations

Human Melanoma-Reactive CD4+ and CD8+ CTL Clones Resist Fas Ligand-Induced Apoptosis and Use Fas/Fas Ligand-Independent Mechanisms for Tumor Killing

1998 • 83 citations

A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation

1999 • 80 citations

Primary melanoma tumour regression associated with an immune response to the tumour‐associated antigen melan‐A/MART‐1

2001 • 79 citations

Cutting Edge: The Tumor Counterattack Hypothesis Revisited: Colon Cancer Cells Do Not Induce T Cell Apoptosis Via the Fas (CD95, APO-1) Pathway

2000 • 77 citations

Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene.

1999 • 76 citations

Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms

2000 • 73 citations

Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35).

1998 • 71 citations

Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy

2001 • 69 citations

Class I Major Histocompatibility Complex Anchor Substitutions Alter the Conformation of T Cell Receptor Contacts

2001 • 66 citations

Resistance to Fas-mediated Apoptosis of Peripheral T Cells in Human T Lymphocyte Virus Type I (HTLV-I) Transgenic Mice with Autoimmune Arthropathy

1997 • 63 citations

Reducing supply current harmonics

1998 • 62 citations

Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short).

2001 • 60 citations

A Novel Autocrine Pathway of Tumor Escape from Immune Recognition: Melanoma Cell Lines Produce a Soluble Protein That Diminishes Expression of the Gene Encoding the Melanocyte Lineage Melan-A/MART-1 Antigen Through Down-Modulation of Its Promoter

2001 • 59 citations

A comparative study of Fas and Fas-ligand expression during melanoma progression

2000 • 57 citations

Antitumor Immunity at Work in a Melanoma Patient

1999 • 48 citations

Inhibition of homologue of Slimb (HOS) function sensitizes human melanoma cells for apoptosis.

1999 • 37 citations

Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy

2001 • 35 citations

Recognition of Melanoma-Derived Antigens by CTL: Possible Mechanisms Involved in Down-Regulating Anti-Tumor T-Cell Reactivity

1998 • 33 citations

Immunophenotypic characterization of human primary and metastatic melanoma infiltrating leukocytes.

1996 • 23 citations

Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of Melan-A/MART-1

2000 • 21 citations

Amino Acid Substitutions in the Melanoma Antigen Recognized by T Cell 1 Peptide Modulate Cytokine Responses in Melanoma-Specific T Cells

2000 • 8 citations